The cannabis industry has been booming with a massive amount of propensity toward the future for some time now, but several companies have come to light with large market caps and even larger ideas to completely transform the cannabis space. These higher market cap companies have a large amount of promise due to being leaders in their field respectively, but it does look as though the upside potential has yet to come.
One of the main companies that should come as no surprise is the company Canopy Growth (CGC ). Canopy has been one of the largest cannabis stocks for some time now. One of the most promising aspects of investing in Canopy seems to be the impending legal recreational cannabis that will hit the market in Canada on October 17th. Many have been waiting for this to occur given that a large amount of the cannabis space is still dependent on speculation due to its infancy as a market. The company has also recently announced a partnership with Constellation Brands (STZ) which will likely help them to begin distributing new types of products such as cannabis-infused beverages and more. This could become one of the largest parts of the cannabis industry as a whole in the near future, and is one of the main reasons that so many investors are looking at this company for growth over the next few years.
The next company and one that is a household name by this point is Aurora Cannabis (ACBFF) The company currently has the second largest market cap of all marijuana stocks which can partly be attributed to their acquisition of the company MedReleaf earlier in this year. The company is an established brand in many countries around the world, and has been a large player in the cannabis growing space for some time now. Aurora has also been working to offer many different services to the cannabis space given their large expertise. Aurora continues to have large growth plans for the future, and investors should continue to watch this company in the coming months to years.
The company GW Pharmaceuticals (GWPH) is a large player in the cannabis space, but not in the traditional sense of the market. GW has been working to get various cannabis-derived drugs approved by the FDA in the U.S. for some time now. The company was the first to receive an FDA approval for a cannabis based drug in the U.S. several months ago, and continue to break ground in new spaces throughout the pharmaceutical uses of the cannabis plant.
The last company on the list is one of the smaller guys in the market, but one with a large amount of promise for the future. Beleave Inc (BLEVF) has been a producer of medical cannabis in Canada for a few years now. The company states that they are a licensed Canadian biotech company and states further that their “larger strategy is to obtain cultivation and sales licenses and build out North American and European distribution channels. Beleave then hopes to expand production and capitalize on expected demand-growth spurred by cannabis legalization across Canada and in select US states.” Beleave remains a company with a large amount of potential for the coming years.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and Beleave Inc., Midam has been paid $200,000 from the company and ZERO shares of Beleave Inc. for a duration of 6 weeks beginning June 18, 2018 and ending July 31, 2018 NOW EXTENDED TO 8/10/2018. We may buy or sell additional shares of (BLEVF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
